Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Nicotinamide vs Kligman Formula in Melasma
NCT05790577Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2022
- Primary completion
- Feb 2023
- Countries
- 1
- Modality
- Small Molecules
- Conditions
- melasma
01
Overview
Phase 2, randomised trial of metformin 1% gel and nicotinamide in melasma. Primary endpoint: Comparison of 30% Metformin and 2% Nicotinamide lotion with Kligman formula in the treatment of Melasma at 12 weeks. Started Feb 2022; status: completed.
02
Design
- Study design
- Randomized
03
Who it enrols
Adults aged 18-50 with melasma, excluding those pregnant or taking oral treatments for melasma.
04
Endpoints
Primary
Comparison of 30% Metformin and 2% Nicotinamide lotion with Kligman formula in the treatment of Melasma
Beyond the preview
Go deeper on NCT05790577.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05790577.